Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the implications for its product, briquilimab, which affected the company's financial and clinical prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is November 18, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which negatively impacted the prospects of its products, including briquilimab [5] - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is reminding investors of Jasper Therapeutics, Inc. about the upcoming lead plaintiff deadline for a securities class action lawsuit, which is set for November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 18, 2025 deadline [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and procedures, which could negatively impact the regulatory and commercial prospects of its products, particularly briquilimab [5]. - The claims suggest that the company's public statements were materially false and misleading, leading to investor damages when the true details became known [5].

Summary of Jasper Therapeutics Conference Call Company Overview - **Company**: Jasper Therapeutics (NasdaqCM: JSPR) - **Date of Conference**: November 12, 2025 Key Points Industry and Product Insights - **Product**: Bromelamab, a drug under investigation for conditions related to mast cell-mediated diseases, including Chronic Spontaneous Urticaria (CSU) and asthma [1][2] - **Clinical Trials**: Ongoing studies to evaluate the efficacy and safety of bromelamab in various cohorts, particularly focusing on patient responses and dosing strategies [4][20] Clinical Data and Findings - **Patient Response Rates**: In a recent study, only 2 out of 10 patients showed complete responses, contrasting with previous studies where response rates were around 60-70% [3][4] - **Investigation of Anomalous Results**: The company is investigating the patient selection process and study conduct at a specific site that enrolled five patients, which may have skewed results [5][6] - **Pharmacokinetics (PK) and Tryptase Levels**: Serum concentrations of bromelamab were consistent with previous studies, indicating that the drug was effectively administered [2] Future Actions and Studies - **Redosing Strategy**: All patients will receive at least three doses to identify any late responders and gather safety data on repeat dosing [6][26] - **Enhanced Patient Selection**: Stricter inclusion-exclusion criteria are being implemented to ensure accurate diagnosis of CSU by expert physicians [8][9] - **Asthma Study Update**: The asthma study was halted due to concerns over the drug lot used, but data from 12-15 patients will be available by the end of the year [10][11] Upcoming Data and Expectations - **Phase 2B Study Plans**: The company plans to initiate a Phase 2B study in mid-2026, based on the data collected from ongoing studies [20] - **Data Availability**: A significant amount of data, including redosing results and safety profiles, is expected to be available in early Q1 of the following year [22][26] Safety and Efficacy Considerations - **Safety Data Importance**: The safety of repeat dosing at 240 mg is a critical focus, as previous data indicated a high efficacy rate with this dosage [6][24] - **Long-term Follow-up**: The company will conduct long-term follow-up on patients to assess the safety and efficacy of the treatment [26] Conclusion - **Overall Sentiment**: The company remains optimistic about the potential of bromelamab, emphasizing the importance of understanding patient selection and drug efficacy in future studies [19][20]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and lack of compliance with manufacturing regulations [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false statements regarding its manufacturing controls and procedures, which negatively impacted the company's financial and clinical prospects [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. regarding a federal securities class action lawsuit, with a lead plaintiff deadline set for November 18, 2025 [2][5]. Group 1: Legal Action and Investor Information - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper and its executives violated federal securities laws by making false or misleading statements and failing to disclose critical information regarding their manufacturing processes and product suitability for clinical trials [5]. - Specific allegations include a lack of necessary controls for third-party manufacturers, which increased the risk of confounding study results and negatively impacted the regulatory and commercial prospects of Jasper's products, particularly briquilimab [5]. - Following a press release on July 7, 2025, regarding issues with a drug product lot, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. Group 3: Company Developments - The press release indicated that Jasper was halting development in asthma and SCID, and would implement cost-cutting measures, including potential restructuring, to extend its financial runway [6]. - Jasper's prior claims of having a strong balance sheet and cash runway extending through the third quarter of 2025 were contradicted by the announcement of these measures [6].

Summary of Jasper Therapeutics Conference Call Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Industry**: Biotechnology - **Lead Asset**: Bricillimab, a monoclonal antibody in clinical trials for chronic spontaneous urticaria (CSU), chronic inducible urticaria, and asthma - **Mechanism**: Bricillimab binds to Kit, a primary survival pathway on mast cells, leading to mast cell apoptosis [1][1][1] Key Points on Urticaria Landscape - Recent launches of Remibrutinib and Dupixent provide new options for CSU patients, who previously had limited choices [2][2][2] - Current treatment approaches can either inhibit mast cells or deplete them, with bricillimab being one of the few that can deplete mast cells [4][4][4] Efficacy and Safety of Bricillimab - Bricillimab shows a nine-day half-life, allowing for a superior safety profile due to its ability to clear and restore signaling to other cells [8][8][8] - Initial clinical data indicates that at the 240 mg dose, there were 100% complete responses in a small cohort, suggesting strong efficacy [23][23][23] - Safety data shows a lower incidence and severity of Kit-related adverse events compared to Barzolvolimab, with a median time to resolution of neutrophil decreases being only 15 days [28][28][28] Clinical Trials and Future Data - The Beacon study is a dose escalation study that has shown promising results, with plans for repeat dosing data to be released in Q4 [24][24][24] - An investigation into anomalous patient responses in July led to a thorough audit and confirmed that the drug product was not at fault [32][32][32] - Upcoming data in Q1 will include results from new patients and longer-term follow-up on existing cohorts [56][56][56] Competitive Landscape - Bricillimab is positioned as a potentially superior option compared to Barzolvolimab, with a focus on both efficacy and safety [16][16][16] - The company is also monitoring other targets like MRGPRX2, which may not deplete mast cells but could play a role in treatment [77][77][77] Financial Outlook - Jasper Therapeutics has sufficient cash to fund operations into Q3 of the following year, but will need additional capital for the phase 2B study [93][93][93] - Potential funding strategies include capital raises or clinical co-development partnerships [102][102][102] Future Directions - The company plans to start a phase 2B study in CSU by mid-2026, aiming to optimize dosing for both efficacy and safety [66][66][66] - There is interest in expanding into asthma, with initial results expected in Q4, which could lead to strategic partnerships [112][112][112]

Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the regulatory prospects of its products, particularly briquilimab [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The failure to disclose these issues allegedly led to an overstatement of Jasper's business and financial prospects, resulting in investor damages when the truth was revealed [5].

Product Development - The company is focused on developing therapeutics for mast cell driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma [121]. - The lead product candidate, briquilimab, demonstrated a rapid onset of clinical efficacy with complete responses observed as early as week 2 post-dose [125]. - In the Phase 1b/2a BEACON study for CSU, briquilimab showed UAS7 reductions of up to 29 points at the 120mg Q12W dose level [125]. - In the Open Label Extension study, 73% of participants achieved a complete response at the week 12 assessment with briquilimab at 180mg Q8W [129]. - The Phase 1b/2a SPOTLIGHT study for CIndU reported that 93% of participants in the 40mg and 120mg cohorts achieved a clinical response [136]. - The company halted enrollment in the ETESIAN study due to concerns over drug product lot efficacy, with results expected in the second half of 2025 [132]. - The ongoing investigation into the BEACON study's efficacy results is expected to conclude in Q4 2025 [127]. - The company discontinued the SCID program to focus resources on mast cell disease development programs [133]. - The company aims to broaden its pipeline with additional mast cell indications and next-generation products [134]. Financial Performance - For the three months ended September 30, 2025, the company reported a net loss of $18.7 million, compared to a net loss of $18.6 million for the same period in 2024, reflecting a slight increase in losses [139][153]. - The accumulated deficit as of September 30, 2025, was $307.6 million, indicating ongoing financial challenges [140]. - The company incurred a net loss of $66.7 million for the nine months ended September 30, 2025 [192]. - The company generated negative operating cash flows of $55.3 million for the nine months ended September 30, 2025, compared to $41.5 million for the same period in 2024 [139]. - Research and development expenses for the three months ended September 30, 2025, were $14.4 million, a decrease of $0.1 million from $14.5 million in the same period in 2024 [153][155]. - Research and development expenses increased by $15.7 million from $36.1 million for the nine months ended September 30, 2024 to $51.7 million for the same period in 2025 [167]. - Total program costs for the three months ended September 30, 2025 were $9.3 million, an increase of 6.4% from $8.8 million for the same period in 2024 [161]. - Total program costs for the nine months ended September 30, 2025 were $34.9 million, an increase of 65% from $21.1 million for the same period in 2024 [172]. - General and administrative expenses decreased by $0.6 million from $5.4 million for the three months ended September 30, 2024 to $4.8 million for the same period in 2025 [162]. - General and administrative expenses increased by $1.4 million from $14.9 million for the nine months ended September 30, 2024 to $16.3 million for the same period in 2025 [173]. - Total other income, net decreased by $0.9 million from $1.3 million for the three months ended September 30, 2024 to $0.4 million for the same period in 2025 [163]. - Total other income, net decreased by $2.7 million from $4.0 million for the nine months ended September 30, 2024 to $1.3 million for the same period in 2025 [174]. Funding and Capital Management - The company entered into an underwriting agreement on September 18, 2025, and closed a public offering on September 22, 2025, raising net proceeds of $27.5 million from the issuance of 11,670,707 shares of common stock [138]. - The company plans to monitor expenses and raise additional capital through public and private equity, debt financings, and strategic alliances [141]. - The company anticipates needing substantial additional funding to support ongoing operations and product development [182]. - As of September 30, 2025, $93.5 million remains available under the ATM Prospectus and $170.0 million under the Shelf Registration Statement [181]. - The company filed a new universal shelf registration statement allowing the sale of up to $263.5 million in various securities as of September 30, 2025 [178]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $34.6 million, down from $47.5 million in the same period in 2024 [195][196]. Corporate Actions - The company implemented a corporate reorganization on July 8, 2025, resulting in a workforce reduction of approximately 50%, equating to 20 employees, and incurred a total cost of approximately $1.8 million related to severance payments [137][139]. - The company has leased approximately 25,900 square feet of office space in Redwood City, California, with rent commitments of $1.8 million due within the next 12 months [187]. - The company has contractual obligations related to license agreements with Stanford, including milestone payments of up to $9.0 million [188][189]. Risks and Challenges - The company is subject to risks associated with the development of new drug candidates, which may lead to unforeseen expenses and delays [182]. - The company does not currently have a sales and marketing infrastructure to support the commercial launch of its product candidates, which may require significant investment prior to product approval [144]. - The company expects its expenses to increase substantially as it advances product candidates through clinical trials and establishes a sales and marketing infrastructure [142].